JPMorgan Chase & Co. Issues Positive Forecast for Scholar Rock (NASDAQ:SRRK) Stock Price

Scholar Rock (NASDAQ:SRRK) had its price target raised by JPMorgan Chase & Co. from $47.00 to $50.00 in a report issued on Monday,Benzinga reports. The firm currently has an overweight rating on the stock.

Other research analysts have also recently issued research reports about the stock. Wolfe Research assumed coverage on shares of Scholar Rock in a report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, January 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Truist Financial increased their target price on Scholar Rock from $44.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Finally, Citigroup raised their price target on Scholar Rock from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Four analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $54.36.

Scholar Rock Stock Performance

Shares of SRRK opened at $40.26 on Monday. Scholar Rock has a 1 year low of $22.71 and a 1 year high of $49.82. The stock has a market capitalization of $4.63 billion, a PE ratio of -11.74 and a beta of 0.70. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.95 and a current ratio of 6.95. The stock has a 50-day simple moving average of $45.16 and a 200-day simple moving average of $39.73.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.10. During the same quarter in the previous year, the business earned ($0.64) EPS. On average, analysts predict that Scholar Rock will post -2.42 earnings per share for the current fiscal year.

Insider Activity at Scholar Rock

In related news, insider Mo Qatanani sold 8,484 shares of Scholar Rock stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $47.07, for a total transaction of $399,341.88. Following the sale, the insider directly owned 98,445 shares in the company, valued at $4,633,806.15. This trade represents a 7.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jing L. Marantz sold 4,157 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $193,425.21. Following the completion of the sale, the insider directly owned 126,012 shares of the company’s stock, valued at approximately $5,863,338.36. This trade represents a 3.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 207,464 shares of company stock worth $9,157,423 in the last ninety days. Company insiders own 13.30% of the company’s stock.

Hedge Funds Weigh In On Scholar Rock

Hedge funds have recently made changes to their positions in the company. IFP Advisors Inc lifted its holdings in shares of Scholar Rock by 294.1% in the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after purchasing an additional 450 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Scholar Rock in the 4th quarter valued at about $30,000. Summit Securities Group LLC purchased a new position in Scholar Rock during the 4th quarter worth approximately $31,000. Ramirez Asset Management Inc. purchased a new position in Scholar Rock during the 3rd quarter worth approximately $37,000. Finally, EverSource Wealth Advisors LLC increased its position in Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after buying an additional 525 shares during the period. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).